替雷利珠单抗联合化疗治疗Ⅲb~Ⅳ期非小细胞肺癌的效果  

The efficacy of combination therapy with tislelizumab and chemotherapy in the treatment of stage IIIb~IV non-small cell lung cancer

作　　者：刘爽 刘倩 庞茜茜 汤建华[2] 张鹤鸣[2] 张志华[3] LIU Shuang;LIU Qian;PANG Qian-qian;TANG Jian-hua;ZHANG He-ming;ZHANG Zhi-hua(Hebei Key Laboratory of Neuropharmacology,School of Pharmacy,Hebei North University,Zhangjiakou 075031,China;Department of Respiratory Medicine,The First Affiliated Hospital of Hebei North University,Zhangjiakou 075061,China;Department of Pharmacy,The First Affiliated Hospital of Hebei North University,Zhangjiakou 075061,China)

机构地区：[1]河北北方学院药学院河北省神经药理学重点实验室,河北张家口075031 [2]河北北方学院附属第一医院药学部,河北张家口075061 [3]河北北方学院附属第一医院呼吸内科,河北张家口075061

出　　处：《实用医院临床杂志》2024年第3期112-116,共5页Practical Journal of Clinical Medicine

基　　金：河北省医学科学研究重点课题(编号:20180828)。

摘　　要：目的探讨替雷利珠单抗联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法选择2021年2月至2022年5月晚期NSCLC患者72例,随机数字表法分为对照组和研究组各36例。对照组给予紫杉醇^(+)卡铂化疗,研究组在对照组的基础上另给予替雷利珠单抗静脉滴注。比较2组患者近期抗肿瘤疗效、肿瘤标志物水平[鳞癌抗原(SCC)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)及糖类抗原125(CA125)]、免疫功能、安全性及预后生存情况。结果研究组客观缓解率、临床控制率高于对照组(P<0.05)。研究组治疗后SCC、CEA、NSE及CA125均低于对照组(P<0.001);CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(均P<0.001)。两组各项药物不良反应发生率比较,差异无统计学意义(P>0.05)。研究组累积生存率(72.22%vs 47.22%)高于对照组(P<0.05)。结论替雷利珠单抗联合化疗治疗晚期NSCLC可提高临床疗效,降低肿瘤标志物水平,改善免疫功能,不良反应耐受,并可提高生存率。Objective To investigate the clinical effect of combination of tislelizumab and chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Seventy-two patients with advanced NSCLC admitted to our hospital from February 2021 to May 2022 were selected.The patients were divided into a control group and a study group by using random number table method,36 in each group.The control group was given paclitaxel^(+)carboplatin.The study group was given the additional treatment of tierellizumab on the basis of the control group.The short-term anti-tumor efficacy,levels of tumor markers such as squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and carbohydrate antigen 125(CA125),immune function,safety and prognosis were compared between the two groups.Results The objective remission rate and clinical control rate in the study group were higher than that in the control group(P<0.05).After treatment,the levels of SCC,CEA,NSE and CA125 in the study group were lower than those in the control group(all P<0.001).After treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higherand CD8^(+)was lower in the study group than those in the control group(all P<0.001).The incidence of adverse drug reactions in the two groups was similar(P>0.05).The cumulative survival rate of the study group was higher than that of the control group(P<0.05).Conclusions Tislelizumab combined with chemotherapy can improve the clinical efficacy.It can reduce the level of tumor markers,improve the immune function and the tolerance of adverse reactions.It also improves the survival rate of patients with advanced NSCLC.

关 键 词：非小细胞肺癌 晚期 替雷利珠单抗 化疗 免疫 生存预后 

分 类 号：R734[医药卫生—肿瘤]